Takeda spins out a pipeline of ‘interesting but still difficult’ psych drugs in $2B deal as it wraps up a post-merger R&D shakeout
Back at JP Morgan in January, I had a sit-down with Takeda R&D chief Andy Plump, who spelled out plans to license out rights to a slate of experimental psychiatry drugs — one of the last R&D deals left to be done after the big Shire buyout was completed a year before.
The therapies, he told me, were “very interesting but still difficult.” And now they are in the hands of Neurocrine Biosciences, which will explore their full potential after committing to a $2 billion deal to see exactly what they are worth.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.